Skip to main content
. Author manuscript; available in PMC: 2010 Feb 10.
Published in final edited form as: Lancet Neurol. 2010 Jan;9(1):119. doi: 10.1016/S1474-4422(09)70299-6

Figure 1. Illustration of biomarker staging of Alzheimer’s disease.

Figure 1

Three elderly individuals are placed in order from left to right by use of our proposed biomarker staging scheme. (A) A cognitively normal individual with no evidence of Aβ on PET amyloid imaging with PiB and no evidence of atrophy on MRI. (B) A cognitively normal individual who has no evidence of neurodegenerative atrophy on MRI, but has significant Aβ deposition on PET amyloid imaging. (B) An individual who has dementia and a clinical diagnosis of Alzheimer’s disease, a positive PET amyloid imaging study, and neurodegenerative atrophy on MRI. Aβ=β-amyloid. PiB=Pittsburgh compound B.